Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 12,216,359	$ 16,612,315
Research and development tax incentive receivable	188,771	186,507
Prepaid assets and other current assets	1,555,309	2,226,344
Total current assets	13,960,439	19,025,166
Operating lease right-of-use asset, net	177,473	196,044
Property and equipment, net	2,226,399	3,078,342
Note receivable - Augmenta	1,839,692	1,812,975
Other assets	7,688	7,688
Total assets	18,211,691	24,120,215
Current liabilities:
Accounts payable	1,344,431	919,607
Accrued compensation		4,430
Deferred research grant revenue	151,000	126,000
Current portion of operating lease liability	81,412	80,625
Total current liabilities	1,576,843	1,130,662
Operating lease liability, net of current portion	91,524	110,094
Total liabilities	1,668,367	1,240,756
Commitments and contingencies (see Note 4)
Stockholders’ equity:
Common stock; $0.001 par value, 90,000,000 shares and 45,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively; 36,193,085 shares issued and outstanding	36,193	36,193
Additional paid-in capital	120,804,884	120,070,983
Accumulated other comprehensive loss	(157,964)	(139,295)
Accumulated deficit	(104,139,789)	(97,088,422)
Total stockholders’ equity	16,543,324	22,879,459
Total liabilities and stockholders’ equity	$ 18,211,691	$ 24,120,215